Painreform Announces Plans To Commence Second Part Of Phase 3 Clinical Trial To Evaluate PRF-110 In Patients Undergoing Bunionectomy Surgery Following FDA Review Of Drug Master File
Portfolio Pulse from Benzinga Newsdesk
Painreform has announced plans to commence the second part of its Phase 3 clinical trial for PRF-110 in patients undergoing bunionectomy surgery. The trial is expected to start in mid-Q4 2023, with results anticipated in mid-2024. This follows a review of the Drug Master File by the FDA.
September 11, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Painreform's announcement of the commencement of the second part of its Phase 3 clinical trial for PRF-110 could potentially impact its stock. The trial is set to begin in mid-Q4 2023, with results expected in mid-2024.
The announcement of a clinical trial's progression is typically seen as positive news for a pharmaceutical company, as it indicates progress in the development of a potential product. This could lead to increased investor confidence in the company, potentially leading to a rise in the stock price. However, the actual impact will depend on various factors, including the overall market conditions and investor sentiment towards the biotech sector.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100